Menactra

Menactra
  • Contraindication

    Severe allergic reaction (eg, anaphylaxis) following a previous dose of vaccine that contained meningococcal capsular polysaccharide, diphtheria toxoid, or CRM197 (diphtheria toxoid carrier protein), or to any component of Menactra® vaccine

  • Side effects

    Adverse reactions of the body to vaccination include: loss of appetite; sleep disturbance; weakness; apathy; vomit; fever; irritability; nervousness; pain, redness and swelling at the injection site; headache.

Menactra

2000 UAH
  • Producing country:United States (USA)
  • Composition and form of release:Solution for injections.

Against what:
coronavirusMeningococcal infection

note_alt Sign up for vaccinations

Application

Before use, it is necessary to visually assess the vaccine for the presence of foreign impurities or color changes. The vaccine should not be used if any of these conditions are present.
Menactra® vaccine is administered as a single dose of 0.5 ml intramuscularly.

  • Indication

    The vaccine is intended for active immunization against meningococcal infection caused by Neisseria meningitidis of serogroups A, C, Y and W-135 in persons aged 9 months to 55 years. Menactra® vaccine does not prevent disease caused by N. meningitidis of serogroup B.